Biogen’s Aduhelm Price Cut Prompts Medicare Premium Review (1)

Biogen Inc.’s decision last month to cut the price of its Alzheimer’s drug in half prompted the top U.S. health official to order a review of Medicare premium hikes tied to the drug.

Health and Human Services Secretary Xavier Becerra instructed the Centers for Medicare & Medicaid Services to reassess the planned member premium increases for 2022 Medicare coverage, according to a statement Monday.

The high price of Aduhelm -- initially $56,000 a year -- combined with uncertainty over how many patients might take it drove large increases in Medicare premiums this year. About half of the annual increase ...